Articles
Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data

https://doi.org/10.1016/S2213-2600(15)00157-5Get rights and content

Summary

Background

There is no universal consensus on the best staging system for chronic obstructive pulmonary disease (COPD). Although documents (eg, the Global Initiative for Chronic Obstructive Lung Disease [GOLD] 2007) have traditionally used forced expiratory volume in 1 s (FEV1) for staging, clinical parameters have been added to some guidelines (eg, GOLD 2011) to improve patient management. As part of the COPD Cohorts Collaborative International Assessment (3CIA) initiative, we aimed to investigate how individual patients were categorised by GOLD 2007 and 2011, and compare the prognostic accuracy of the staging documents for mortality.

Methods

We searched reports published from Jan 1, 2008, to Dec 31, 2014. Using data from cohorts that agreed to participate and had a minimum amount of information needed for GOLD 2007 and 2011, we did a patient-based pooled analysis of existing data. With use of raw data, we recalculated all participant assignments to GOLD 2007 I–IV classes, and GOLD 2011 A–D stages. We used survival analysis, C statistics, and non-parametric regression to model time-to-death data and compare GOLD 2007 and GOLD 2011 staging systems to predict mortality.

Findings

We collected individual data for 15 632 patients from 22 COPD cohorts from seven countries, totalling 70 184 person-years. Mean age of the patients was 63·9 years (SD 10·1); 10 751 (69%) were men. Based on FEV1 alone (GOLD 2007), 2424 (16%) patients had mild (I), 7142 (46%) moderate (II), 4346 (28%) severe (III), and 1670 (11%) very severe (IV) disease. We compared staging with the GOLD 2007 document with that of the new GOLD 2011 system in 14 660 patients: 5548 (38%) were grade A, 2733 (19%) were grade B, 1835 (13%) were grade C, and 4544 (31%) were grade D. GOLD 2011 shifted the overall COPD severity distribution to more severe categories. There were nearly three times more COPD patients in stage D than in former stage IV (p<0·05). The predictive capacity for survival up to 10 years was significant for both systems (p<0·01) but area under the curves were only 0·623 (GOLD 2007) and 0·634 (GOLD 2011), and GOLD 2007 and 2011 did not differ significantly. We identified the percent predicted FEV1 thresholds of 85%, 55% and 35% as better to stage COPD severity for mortality, which are similar to the ones used previously.

Interpretation

Neither GOLD COPD classification schemes have sufficient discriminatory power to be used clinically for risk classification at the individual level to predict total mortality for 3 years of follow-up and onwards. Increasing intensity of treatment of patients with COPD due to their GOLD 2011 reclassification is not known to improve health outcomes. Evidence-based thresholds should be searched when exploring the prognostic ability of current and new COPD multicomponent indices.

Funding

None.

Introduction

Chronic obstructive pulmonary disease (COPD) affects about 328 million people worldwide and accounts for 4 million deaths every year.1 To address the growing global burden of COPD, efforts have been made to increase awareness and to standardise treatment models. The most influential effort has been the Global Initiative for Chronic Obstructive Lung Disease (GOLD), which was launched in 1997 as a joint effort between the US National Institutes of Health and WHO.2 Traditionally, GOLD and other similar initiatives have classified patients' COPD severity through thresholds of forced expiratory volume in 1 sec (FEV1). However, in 2011 the GOLD committee added clinical parameters (ie, a history of exacerbation and respiratory symptoms) to FEV1 to improve clinical management of patients with COPD.3 Although the GOLD staging system was designed to guide therapy, it is commonly used for prognostication.4, 5 The usefulness of both the 2007 and 2011 GOLD staging systems to predict mortality of patients with COPD is debated, with small, partial studies giving largely inconclusive results. To resolve this important issue, we obtained and pooled individual data for 15 632 patients from 22 COPD cohorts from seven countries and compared the prognostic power of the 2011 versus 2007 GOLD classification schemes to predict mortality.6

Research in context

Evidence before this study

COPD affects many people worldwide, but its definition and staging remain controversial. Before 2011, the GOLD classification scheme was based exclusively on forced expiratory volume in 1 s (FEV1) thresholds. The 2011 GOLD document proposed a new classification scheme based on spirometry, the history of exacerbations, and symptoms. Since the publication of that document, several reports have compared it with the old 2007 grading, with somewhat conflicting results.

Added value of this study

We obtained and pooled individualised data from 22 published COPD cohorts, totalling 15 632 patients that contributed 70 184 person-years of follow-up to the study. The most important finding was that the 2011 GOLD classification scheme did not improve the prediction of mortality, as compared to the 2007 classification. Through the large size of the sample, we were able to overcome many of the limitations of individual studies, and had a large statistical power for most subanalyses. Therefore, we conclude that the more complicated GOLD 2011 classification scheme is no better than the simpler previous one based on spirometry only. The use of the 2011 staging system resulted in many more patients with the most severe disease (more in GOLD D than in GOLD IV), making them seem more ill. Further, GOLD class C might be superfluous because patients in this category have a similar mortality as those in class B and treatment strategies do not differ between the two groups.

Implications of all the available evidence

Neither GOLD COPD classification schemes had sufficient discriminatory power to be used clinically for risk-classification at the individual level to predict total mortality for 3 years of follow-up and up to 10 years. It is yet to be established if an increased intensity of treatment of patients with COPD by their GOLD 2011 reclassification improves their health outcomes.

Section snippets

Study population

We searched reports published from Jan 1, 2008, to Dec 31, 2014, and obtained 28 reports as per our research protocol (appendix). Members of the COPD Cohorts Collaborative International Assessment [3CIA] Steering Committee approached the coordinators of known large, published, prospective cohort studies to gather information about their willingness to participate and the availability of a minimum required set of individual data comprising vital status (up to death, right truncation, or June

Results

We obtained and pooled data for individuals from 22 published COPD cohorts (table 1). 15 632 patients contributed 70 184 person-years of follow-up time to the study.

Based on the 2007 GOLD classification scheme, of 15 882 patients with applicable data, 2424 (16%) had mild (stage I), 7142 (46%) had moderate (stage II), 4346 (28%) had severe (stage III), and 1670 (11%) had very severe (IV) disease (table 1). Based on the GOLD 2011 scheme, of 14 660 patients with applicable data: 5548 (38%) were

Discussion

This is the largest study to evaluate total mortality in patients with COPD according to severity with more than 15 000 patients and 70 000 person-years of follow-up. The most important finding was that the use of the 2007 GOLD classification scheme (based exclusively on FEV1) and the use of the 2011 GOLD classification scheme (based on spirometry, a history of exacerbations, and symptoms) similarly predicted mortality within 10 years. However, although both classification schemes were

References (34)

  • RA Pauwels et al.

    Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary

    Am J Respir Crit Care Med

    (2001)
  • J Vestbo et al.

    Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

    Am J Respir Crit Care Med

    (2013)
  • A Agusti et al.

    Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort

    Eur Respir J

    (2013)
  • JP de Torres et al.

    Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE

    Thorax

    (2014)
  • KF Rabe et al.

    Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

    Am J Respir Crit Care Med

    (2007)
  • P Almagro et al.

    Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study

    PLoS One

    (2014)
  • EA Regan et al.

    Genetic epidemiology of COPD (COPDGene) study design

    COPD

    (2010)
  • Cited by (137)

    • The value of radiomic features in chronic obstructive pulmonary disease assessment: a prospective study

      2022, Clinical Radiology
      Citation Excerpt :

      Some radiomic features also correlated with the change in health status and exacerbation at 1-year follow-up. In previous studies, exacerbation history, lung function, and the BODE index were used as predictors for COPD exacerbation.29–31 In addition to these risk factors, original_flatness can provide additional value for exacerbation prediction according to the present analysis.

    • A new, three-dimensional approach to the GOLD COPD assessment tool

      2022, Respiratory Medicine and Research
      Citation Excerpt :

      In this scheme, patients were classified in the upper quadrants (C or D) either if they suffered exacerbations or if they had an FEV1 < 50%. However, this new classification scheme was found to be not better at predicting mortality than GOLD2007, although it did predict better future exacerbations [3,4]. Since 2017, a new ABCD classification was adopted (GOLD2017), and continued to be used in subsequent versions of the GOLD document.

    • Effects of influenza vaccination on clinical outcomes of chronic obstructive pulmonary disease: A systematic review and meta-analysis

      2021, Ageing Research Reviews
      Citation Excerpt :

      More pragmatic RCTs and observational studies with more sophisticated design are warranted to further confirm the cost effects of influenza vaccination on COPD patients. Several suggestions and confounding factors could be considered in the future study: 1) a prospective cohort study or retrospective subgroup analysis based on the GOLD spirometric grading systems (GOLD 1–4 based on post-bronchodilator FEV1) could help to elucidate the cost effect of influenza vaccination in COPD patients with different airflow limitation; 2) although the spirometric severity is significantly related to the risk of exacerbation and death, the FEV1 by itself lacks sufficient precision to predict exacerbation or mortality in clinics (Soriano et al., 2015), it is reported that a history of exacerbation might be a better predictor for the exacerbations risk (Hurst et al., 2010), therefore a prospective cohort study established on the frequent AE (defined as two or more exacerbations per year) or non-frequent AE subtype could better describe the role of influenza vaccination in the control of exacerbations; 3) the type and dose of influenza vaccination (QIV or TIV, live attenuated or inactive influenza vaccine) should be considered, besides, a possible mismatch between the strain lineage recommended for vaccine and the one in circulation should be recorded; 4) more detailed evaluation indicators should be considered including but not limited to the frequency of annual exacerbations/hospitalizations, duration for each exacerbation/hospitalizations, all-cause/respiratory relevant mortality, “early” & “late” lung function change (FEV1, FVC, PEF etc., ≤ and > 3 weeks after vaccination), “early” & “late” exacerbations (≤ and > 3 weeks after vaccination), and any possible systemic or local adverse reactions; 5) a vaccination against influenza usually targets winter with seasonal peak of influenza, however, immunity might need 2–3 weeks to be acquired after vaccination (Vila-Corcoles et al., 2008), therefore, a selection of vaccination timing should allow sufficient period for the acquisition of immunity before influenza season; 6) antibody levels against influenza might fall to a nonprotective levels within a year of vaccination (Beyer et al., 1999), moreover, repeat vaccination might reduce antibody affinity maturation and contribute to lower vaccine effectiveness of seasonal influenza vaccines (Khurana et al., 2019), thus a longer follow-up study might be needed to elucidate the effect of repeated influenza vaccination on the clinical outcome of COPD. Authors’ contributions: Conception and design: JC, WB, YL; Funding acquisition: JC, FW; Acquisition of data: WB, YL; Analysis and interpretation of data: WB, YL, JC, FW, TW, XL, JH, YW; Drafting the manuscript: WB, YL, JC; Revising the manuscript critically for important intellectual content: JC, FW.

    View all citing articles on Scopus
    View full text